Generali Asset Management SPA SGR Raises Stake in Amgen Inc. $AMGN

Key Points

• Generali Asset Management increased its Amgen stake by 32.1% in the fourth quarter, adding 12,414 shares to bring its total holdings to 51,104 shares valued at about $16.7 million.
• Amgen reported better-than-expected quarterly results, posting EPS of $5.15 versus the $4.77 consensus and revenue of $8.62 billion, while revenue rose 5.8% year over year.
• The company also announced a quarterly dividend of $2.52 per share, payable June 5, implying a 3.1% annualized yield; meanwhile, analysts currently view the stock as a Hold with an average price target of $357.12.

Generali Asset Management SPA SGR boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 32.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 51,104 shares of the medical research company's stock after purchasing an additional 12,414 shares during the period. Generali Asset Management SPA SGR's holdings in Amgen were worth $16,727,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of AMGN. Vanguard Group Inc. boosted its holdings in shares of Amgen by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company's stock valued at $17,949,296,000 after acquiring an additional 961,975 shares in the last quarter. Capital International Investors boosted its holdings in shares of Amgen by 1.5% in the third quarter. Capital International Investors now owns 19,192,995 shares of the medical research company's stock valued at $5,414,296,000 after acquiring an additional 282,219 shares in the last quarter. Capital World Investors boosted its holdings in shares of Amgen by 11.5% in the third quarter. Capital World Investors now owns 18,795,474 shares of the medical research company's stock valued at $5,303,578,000 after acquiring an additional 1,935,876 shares in the last quarter. Capital Research Global Investors boosted its holdings in shares of Amgen by 2.7% in the third quarter. Capital Research Global Investors now owns 4,731,290 shares of the medical research company's stock valued at $1,335,168,000 after acquiring an additional 122,631 shares in the last quarter. Finally, Invesco Ltd. boosted its holdings in shares of Amgen by 6.6% in the third quarter. Invesco Ltd. now owns 4,467,287 shares of the medical research company's stock valued at $1,260,668,000 after acquiring an additional 277,031 shares in the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Stock Down 0.7%

Shares of NASDAQ AMGN opened at $328.91 on Friday. The company has a quick ratio of 0.90, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. Amgen Inc. has a 52 week low of $261.43 and a 52 week high of $391.29. The firm has a 50-day moving average price of $355.12 and a 200 day moving average price of $341.81. The stock has a market capitalization of $177.51 billion, a price-to-earnings ratio of 22.89, a price-to-earnings-growth ratio of 3.33 and a beta of 0.44.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm had revenue of $8.62 billion during the quarter, compared to analysts' expectations of $8.58 billion. During the same quarter last year, the business earned $4.90 earnings per share. The business's revenue for the quarter was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities research analysts anticipate that Amgen Inc. will post 22.36 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be paid a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a dividend yield of 3.1%. Amgen's dividend payout ratio (DPR) is 70.15%.

Analysts Set New Price Targets

AMGN has been the topic of several analyst reports. Canaccord Genuity Group initiated coverage on shares of Amgen in a report on Monday, April 20th. They issued a "hold" rating and a $366.00 target price on the stock. Truist Financial lifted their target price on shares of Amgen from $325.00 to $327.00 and gave the company a "hold" rating in a report on Friday, May 1st. Oppenheimer set a $400.00 target price on shares of Amgen and gave the company an "outperform" rating in a report on Thursday, January 29th. Barclays initiated coverage on shares of Amgen in a report on Friday, February 20th. They issued an "equal weight" rating and a $350.00 target price on the stock. Finally, Leerink Partners reaffirmed a "market perform" rating and issued a $355.00 target price on shares of Amgen in a report on Thursday, March 5th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fifteen have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $357.12.

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the firm's stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares in the company, valued at $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.85% of the stock is owned by company insiders.

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.